US Capitol Capsule: In current US budget-cutting climate, was KV naïve in pricing Makena?
This article was originally published in Scrip
KV Pharmaceuticals and its subsidiary Ther-Rx on 1 April gave in to public pressure and sharply cut the price of their newly approved preterm birth prevention drug Makena (hydroxyprogesterone caproate) from $1,500 to $690 per dose. But at a time when the US government is being funded a few weeks at a time – with another potential shutdown looming for 8 April – and Republicans are seeking to slash $4 trillion from the budget, it is surprising the companies appeared to be so naïve that they could get the US taxpayer to pick up much of the expected $4.2 billion annual cost of the drug without stirring controversy.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.